Endosense: Growing Up Fast in AF

Hoping to succeed in the elusive field of atrial fibrillation, Endosense is taking an anti-start-up strategy: focusing more on later-stage commercialization and market launch and less on technology vetting.

By David Cassak

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo